Drug Trial Radar · NCT00640614
Clinical Evaluation of T.R.U.E. TEST® : Safety and Efficacy
Last checked: Nov 19, 2026Latest source record: May 5, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
235
Actual
Start
Apr 2008
Primary completion
Aug 2009
Study completion Oct 2009
Sponsor
- Lead sponsor
- AllerdermIndustry
- Sponsor type
- Industry
- First posted
- Mar 21, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
We propose an open, prospective, multi-center Phase III study to evaluate the diagnostic performance and safety of seven new T.R.U.E. Test allergens: Gold sodium thiosulfate, Hydrocortisone-17-butyrate, Bacitracin, Parthenolide, Methyldibromoglutaronitrile, Disperse blue 106, and Bronopol.Allergen performance and safety will be evaluated in adult patients with suspected contact dermatitis, and in adult patients with a known or suspected sensitization to at least one of the seven allergens.
Conditions
- Contact Dermatitis
Interventions
T.R.U.E. TEST® Skin Patch Test: Dose Response AllergensBiological
Polyvinylpyrrolidone (PVP; excipient 1) Hydrocortisone-17-butyrate, 0.020 mg/cm2 in PVP Hydroxypropylcellulose (HPC; excipient 2) MDBGN, 0.0055 mg/cm2 in PVP Bacitracin, 0.60 mg/cm2 in HPC Gold sodium thiosulfate, 0.075 mg/cm2 in HPC Parthenolide, 0.0030 mg/cm2 in PVP Disperse Blue 106, 0.050 mg/cm2 in PVP Bronopol, 0.25 mg/cm2 in PVP Test patches, with allergens, are placed at day one and removed 48 hours later. The duration of the study lasts 21 days. However, the subject is only exposed to the study allergens for 48 hours.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Diagnostic Performance: Concordance Between Investigational Allergen and Reference Allergen at Day 21Time frame: Visit 5: 21 days after patch application
- Diagnostic Performance: ConcordanceTime frame: Visit 5: 21 days after patch application
- Diagnostic Performance: ConcordanceTime frame: Visit 5: 21 days after patch application
- Diagnostic Performance: ConcordanceTime frame: Visit 5: 21 days after patch application
- Diagnostic Performance: ConcordanceTime frame: Visit 5: 21 days after patch application
- Diagnostic Performance: ConcordanceTime frame: Visit 5: 21 days after patch application
- Diagnostic Performance: ConcordanceTime frame: Visit 5: 21 days after patch application
- Diagnostic Performance: Sensitivity and Specificity: Gold Sodium ThiosulfateTime frame: Visit 5: 21 days after patch application
- Diagnostic Performance: Sensitivity and Specificity: Hydrocortisone-17-butyrateTime frame: Visit 5: 21 days after patch application
- Diagnostic Performance: Sensitivity and Specificity: Methyldibromo-glutaronitrileTime frame: Visit 5: 21 days after patch application
- Diagnostic Performance: Sensitivity and Specificity: BacitracinTime frame: Visit 5: 21 days after patch application
- Diagnostic Performance: Sensitivity and Specificity: ParthenolideTime frame: Visit 5: 21 days after patch application
- Diagnostic Performance: Sensitivity and Specificity: Disperse BlueTime frame: Visit 5: 21 days after patch application
- Diagnostic Performance: Sensitivity and Specificity: BronopolTime frame: Visit 5: 21 days after patch application
Locations
5 sites in 2 countries. Site status is shown where the registry gives one.
River City Dermatology
Little Rock, Arkansas
American Dermatology Associates
Shawnee Mission, Kansas
Dermatology Specialists PSC
Louisville, Kentucky
Winthrop University Hospital
Mineola, New York
Odense University Hospital
Odense C, Denmark
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.